Glaxosmithkline (GSK)

 

Latest News

Director Deals - GlaxoSmithKline PLC (GSK)

Simon Dingemans, Financial Director, exercised 216 shares in the company on the 1st December 2016 at a price of 1247.00p. ...

Director/PDMR Shareholding

RNS Number: 8685Q GlaxoSmithKline PLC 02 December 2016 GlaxoSmithKline plc (the ' Company ') Transaction notification 1. Details of PDMR/person closely associated with them ('PCA') a) Name Mr S Dingemans b) Position/status Chief Financial Officer c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market partic...

GSK files closed triple therapy for COPD in EU

GlaxoSmithKline and Innoviva have announced the filing by GSK of a regulatory submission with the European Medicin...

GSK files closed triple therapy for COPD in EU

RNS Number: 8557Q GlaxoSmithKline PLC 02 December 2016 Issued: Friday, 2 December 2016, London UK - LSE Announcement GSK files EU regulatory submission for once-daily closed triple combination therapy FF/UMEC/VI for patients with COPD GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the filing by G...

All News

DateHeadlineSource
02-12-16Director Deals - GlaxoSmithKline PLC (GSK)StockMarketWire
02-12-16Director/PDMR ShareholdingRNS
02-12-16GSK files closed triple therapy for COPD in EUStockMarketWire
02-12-16GSK files closed triple therapy for COPD in EURNS
02-12-16GSK confirms Japan approval for Relvar Ellipta StockMarketWire
02-12-16Relvar Ellipta approved in Japan for COPDRNS
01-12-16Total Voting RightsRNS
30-11-16Floats, mergers and meltdowns: 21 years of the FTSE 100Interactive Investor
30-11-16Director/PDMR ShareholdingRNS
25-11-16GSK confirms submission for shingles vaccineStockMarketWire
25-11-16EU submission of shingles candidate vaccineRNS
25-11-16Is AstraZeneca plc or GlaxoSmithKline plc the best Black Friday buy?Motley Fool
24-11-16Start of Phase III studies with daprodustatRNS
23-11-16GSK's mepolizumab meets endpointsStockMarketWire
23-11-16Mepolizumab meets endpoints in phase 3 EGPA studyRNS
21-11-16FTSE mixed as miners, oilies drag blue chips southStockMarketWire
21-11-16GSK files closed triple therapy for COPD in US StockMarketWire
21-11-16GSK files closed triple therapy for COPD in USRNS
18-11-16 ViiV launches two phase III studiesStockMarketWire
18-11-16ViiV starts PhIII LA injectable treatment regimenRNS
17-11-16Here are Neil Woodford's latest tradesInteractive Investor
14-11-16Shares rally as Trump goes softInteractive Investor
11-11-16Broker Forecast - Jefferies International issues a broker note on GlaxoSmithKline PLCStockMarketWire
10-11-16Director/PDMR ShareholdingRNS
09-11-16It's Trump! So how come FTSE 100 hasn't crashed? Interactive Investor
08-11-16Block listing Interim ReviewRNS
08-11-16Director/PDMR ShareholdingRNS
04-11-16Director/PDMR ShareholdingRNS
02-11-16Director/PDMR ShareholdingRNS
01-11-1613 dividend stocks among best in EuropeInteractive Investor
01-11-16Total Voting RightsRNS
01-11-16Broker Forecast - JP Morgan Cazenove issues a broker note on GlaxoSmithKline PLCStockMarketWire
28-10-16Director/PDMR ShareholdingRNS
28-10-16Insider: Police investigate dodgy dealsInteractive Investor
27-10-16Director Deals - GlaxoSmithKline PLC (GSK)StockMarketWire
27-10-16Director/PDMR ShareholdingRNS
27-10-16What's moving the FTSE 100?Interactive Investor
27-10-16GSK issues new data on shingles candidate vaccineRNS
27-10-16Broker Forecast - Natixis issues a broker note on GlaxoSmithKline PLCStockMarketWire
26-10-16Director/PDMR ShareholdingRNS

RSS feeds

  • Editorial news feed for LSE:GSK Editorial
  • Regulatory news feed for LSE:GSK Regulatory